Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial

NCT01221402 is registered in ClinicalTrials.gov with North Texas Veterans Healthcare System as lead sponsor.

NCT NCT01221402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial
Lead sponsor
North Texas Veterans Healthcare System
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
November 30, 2015
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aortocoronary saphenous vein bypass graft atherosclerosis, intermediate saphenous vein graft lesions